A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally-administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis
American Journal of Obstetrics and Gynecology Mar 16, 2018
Brand SR, et al. - In women with recurrent vulvovaginal candidiasis, the efficacy and safety of 4 dosing regimens of oral VT-1161 compared to placebo were evaluated. Researchers recognized VT-1161 to be efficacious and safe in treating these patients. In this work, VT-1161 was observed to be well tolerated, with a low incidence of adverse events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
